Ingevity Corp (NGVT) stock
NGVTNYSEChemicals & Allied ProductsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3077% above fair value
$60.02−1.70 (-2.75%)
Close on Nov 16, 2026Market cap $2.06BP/E 40.8Yield –
Ingevity r&d expenses
Research and development expenses are spending on new products and technology.
Ingevity's R&D Expenses for the twelve months ending Jun 30, 2026 was $27.20M, up 1.9% year over year. For fiscal 2025 it was $28.40M, up 15.9% from the year before. Over ten years it grew 5.0% a year on average. The highest annual figure on record is $30.30M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.40M | +15.9% |
| FY2024 | Dec 31, 2024 | $24.50M | -3.5% |
| FY2023 | Dec 31, 2023 | $25.40M | -16.2% |
| FY2022 | Dec 31, 2022 | $30.30M | +15.2% |
| FY2021 | Dec 31, 2021 | $26.30M | +16.4% |
| FY2020 | Dec 31, 2020 | $22.60M | +14.7% |
| FY2019 | Dec 31, 2019 | $19.70M | -8.4% |
| FY2018 | Dec 31, 2018 | $21.50M | +8.6% |
| FY2017 | Dec 31, 2017 | $19.80M | +12.5% |
| FY2016 | Dec 31, 2016 | $17.60M | +1.1% |
| FY2015 | Dec 31, 2015 | $17.40M | +123.1% |
| FY2014 | Dec 31, 2014 | $7.80M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $6.10M | -12.9% |
| Q1 FY2026 | Mar 31, 2026 | $6.70M | -4.3% |
| Q4 FY2025 | Dec 31, 2025 | $7.40M | +13.8% |
| Q3 FY2025 | Sep 30, 2025 | $7.00M | +12.9% |
| Q2 FY2025 | Jun 30, 2025 | $7.00M | -4.1% |
| Q1 FY2025 | Mar 31, 2025 | $7.00M | +2.9% |
| Q4 FY2024 | Dec 31, 2024 | $6.50M | +712.5% |
| Q3 FY2024 | Sep 30, 2024 | $6.20M | -20.5% |
| Q2 FY2024 | Jun 30, 2024 | $7.30M | -8.8% |
| Q1 FY2024 | Mar 31, 2024 | $6.80M | -22.7% |
| Q4 FY2023 | Dec 31, 2023 | $800.00K | -88.9% |
| Q3 FY2023 | Sep 30, 2023 | $7.80M | +2.6% |
| Q2 FY2023 | Jun 30, 2023 | $8.00M | -2.4% |
| Q1 FY2023 | Mar 31, 2023 | $8.80M | +20.5% |
| Q4 FY2022 | Dec 31, 2022 | $7.20M | +2.9% |
| Q3 FY2022 | Sep 30, 2022 | $7.60M | +11.8% |
| Q2 FY2022 | Jun 30, 2022 | $8.20M | +39.0% |
| Q1 FY2022 | Mar 31, 2022 | $7.30M | +10.6% |
| Q4 FY2021 | Dec 31, 2021 | $7.00M | +20.7% |
| Q3 FY2021 | Sep 30, 2021 | $6.80M | +30.8% |
| Q2 FY2021 | Jun 30, 2021 | $5.90M | +9.3% |
| Q1 FY2021 | Mar 31, 2021 | $6.60M | +6.5% |
| Q4 FY2020 | Dec 31, 2020 | $5.80M | +23.4% |
| Q3 FY2020 | Sep 30, 2020 | $5.20M | +6.1% |
| Q2 FY2020 | Jun 30, 2020 | $5.40M | +8.0% |
| Q1 FY2020 | Mar 31, 2020 | $6.20M | +21.6% |
| Q4 FY2019 | Dec 31, 2019 | $4.70M | -9.6% |
| Q3 FY2019 | Sep 30, 2019 | $4.90M | -12.5% |
| Q2 FY2019 | Jun 30, 2019 | $5.00M | -5.7% |
| Q1 FY2019 | Mar 31, 2019 | $5.10M | +2.0% |
| Q4 FY2018 | Dec 31, 2018 | $5.20M | 0.0% |
| Q3 FY2018 | Sep 30, 2018 | $5.60M | +16.7% |
| Q2 FY2018 | Jun 30, 2018 | $5.30M | +12.8% |
| Q1 FY2018 | Mar 31, 2018 | $5.00M | -2.0% |
| Q4 FY2017 | Dec 31, 2017 | $5.20M | +18.2% |
| Q3 FY2017 | Sep 30, 2017 | $4.80M | +23.1% |
| Q2 FY2017 | Jun 30, 2017 | $4.70M | – |
| Q1 FY2017 | Mar 31, 2017 | $5.10M | – |
| Q4 FY2016 | Dec 31, 2016 | $4.40M | – |
| Q3 FY2016 | Sep 30, 2016 | $3.90M | – |
See a number that looks wrong?